Irinotecan, 5-Fluorouracil, and Leucovorin in Colorectal Carcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

February 28, 2001

Primary Completion Date

February 29, 2004

Study Completion Date

April 30, 2004

Conditions
Colorectal Carcinoma
Interventions
DRUG

Irinotecan

Irinotecan by intravenous infusion (needle in a vein in your arm) over 90 minutes immediately followed by intravenous LV and 5-FU weekly for 4 weeks (days 1, 8, 15 and 22) followed by two weeks of no treatment.

DRUG

5-Fluorouracil

Irinotecan by intravenous infusion (needle in a vein in your arm) over 90 minutes immediately followed by intravenous LV and 5-FU weekly for 4 weeks (days 1, 8, 15 and 22) followed by two weeks of no treatment.

DRUG

Leucovorin

Irinotecan by intravenous infusion (needle in a vein in your arm) over 90 minutes immediately followed by intravenous LV and 5-FU weekly for 4 weeks (days 1, 8, 15 and 22) followed by two weeks of no treatment.

DRUG

Tetrathiomolybdate

one 40 mg oral (by mouth) dose of TM three times a day with meals and one 60 mg oral dose (without food) at bedtime beginning at bedtime on day 1 of your first 6-week cycle of treatment. The between meal dose must be taken at least one hour before or one hour after a meal.

Trial Locations (1)

48109

University of Michigan Cancer Center, Ann Arbor

All Listed Sponsors
lead

University of Michigan Rogel Cancer Center

OTHER

NCT00176774 - Irinotecan, 5-Fluorouracil, and Leucovorin in Colorectal Carcinoma | Biotech Hunter | Biotech Hunter